Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.
Ribonucleases are a superfamily of enzymes which operate at the crossroads of transcription and translation, catalyzing the degradation of RNA; they can be cytotoxic because the cleavage of RNA renders indecipherable its information. Ranpirnase is a novel ribonuclease which preferentially degrades tRNA, thus leading to inhibition of protein synthesis and, ultimately, to cytostasis and cytotoxicity. Ranpirnase has demonstrated antitumor activity both in vitro and in vivo in several tumor models. The maximum tolerated dose emerging from phase I studies was 960 g/m(2), with renal toxicity as the main dose-limiting toxicity. A large phase II trial showed that ranpirnase has disease-modifying activity against malignant mesothelioma. Ranpirnase proved to be superior to doxorubicin in a phase III trial, while preliminary results of another large, phase III trial, suggest that the combination of ranpirnase and doxorubicin could be more effective than doxorubicin alone. In all the above studies, ranpirnase seems to act mainly as a cytostatic rather than a cytotoxic drug, stabilizing progressive disease and potentially prolonging patients' survival. Ranpirnase may thus find its niche in combination with doxorubicin for mesothelioma as a second-line therapy, where no standard of care presently exists.
Porta
Camillo
C
Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy.
Paglino
Chiara
C
Mutti
Luciano
L
J Mol Biol. 1996 Apr 19;257(5):992-1007
8632481
Mol Cancer Ther. 2005 May;4(5):835-42
15897248
Cancer Chemother Pharmacol. 2008 Jul;62(2):337-46
18064463
J Natl Cancer Inst. 1990 Jan 17;82(2):151-3
2294226
Blood. 2000 Jul 1;96(1):307-13
10891466
Cell Tissue Kinet. 1988 May;21(3):169-82
3224365
Anticancer Res. 2007 Jan-Feb;27(1A):299-307
17352247
Chem Biol. 2001 May;8(5):405-13
11358688
Cell Mol Life Sci. 1998 Aug;54(8):775-84
9760986
Br J Cancer. 1999 Feb;79(3-4):666-72
10027347
Biotechnol Lett. 2006 Oct;28(20):1615-22
16902846
J Clin Oncol. 2001 Jan 1;19(1):265-72
11134222
Invest New Drugs. 2001;19(3):255-60
11561684
Expert Opin Biol Ther. 2006 Apr;6(4):391-9
16548765
Int J Oncol. 1995 Apr;6(4):889-97
21556617
Cancer Invest. 2005;23(7):643-50
16305992
Chest. 1998 Mar;113(3):723-31
9515850
Cancer Chemother Pharmacol. 1999;44(2):164-9
10412952
Nat Clin Pract Oncol. 2008 Mar;5(3):136-47
18227828
Int J Oncol. 2007 Sep;31(3):663-9
17671695
Mol Biosyst. 2005 Oct;1(4):294-302
16880994
J Clin Oncol. 2002 Jan 1;20(1):274-81
11773179
Anticancer Res. 2000 Mar-Apr;20(2A):1037-40
10810394
Proteins. 1992 Nov;14(3):392-400
1438177
J Biol Chem. 1991 Jan 5;266(1):245-51
1985896
Adv Exp Med Biol. 2007;599:53-9
17727247
BioDrugs. 2008;22(1):53-8
18215091
Adv Exp Med Biol. 2003;530:187-96
14562716
J Biol Chem. 1993 May 15;268(14):10686-93
8486718
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10407-12
9724716
Leukemia. 1998 Aug;12(8):1241-8
9697879
J Natl Cancer Inst. 1996 Jun 5;88(11):747-53
8637029
Int J Oncol. 1992 Dec;1(7):779-85
21584616
J Surg Oncol. 2000 Mar;73(3):164-71
10738271
Cancer Res. 1996 Sep 15;56(18):4180-6
8797589
Semin Oncol. 2005 Jun;32(3):336-50
15988688
Nat Rev Cancer. 2007 Feb;7(2):147-54
17251920
Int J Oncol. 1998 Jul;13(1):11-6
9625797
Cancer Lett. 2007 May 18;250(1):107-16
17084521
Nature. 1955 Jul 2;176(4470):36-7
14394135
Cancer Res. 2000 Apr 1;60(7):1983-94
10766189
Int J Oncol. 1993 Jul;3(1):57-64
21573326
Cell Tissue Kinet. 1990 May;23(3):237-46
2357721
In Vivo. 2007 Sep-Oct;21(5):721-8
18019404
Experientia. 1954 Dec 15;10(12):500-1
14353090
Curr Pharm Biotechnol. 2007 Dec;8(6):318-9
18289038
Blood. 2001 Jan 15;97(2):528-35
11154233
Mol Cell Biol Res Commun. 2000 Aug;4(2):122-8
11170843